Results 51 to 60 of about 5,124 (246)
TH Open, 2019 Idarucizumab is a humanized antigen binding fragment (Fab) of a recombinant anti-dabigatran monoclonal antibody (IgG1-kappa) that allows rapid and sustained reversal of dabigatran-induced anticoagulation in case of bleeding or urgent surgery.
Nicolas Gendron +5 more
doaj +1 more source
Frontiers in Neurology, 2019 We report a case of intravenous thrombolysis in acute ischemic stroke of anterior choroidal artery following the antagonization of dabigatran with idarucizumab.
Maren Hieber, Juergen Bardutzky
doaj +1 more source
Tap chi nghien cuu y hoc, 2023 Non-vitamin K antagonist oral anticoagulants are used more and more popularly because they are more effective than vitamin K antagonists. Dabigatran is the only non–vitamin K antagonist oral anticoagulant with an antidote, idarucizumab, in Vietnam.
M. D. Ton +2 more
semanticscholar +1 more source
Direkt orális antikoagulánsok a kardiológiában | Direct oral anticoagulants in cardiology [PDF]
, 2016 Absztrakt Az antithromboticus gyógyszeres kezelés napjaink gyakorlati medicinájának egyik fontos, de sokszor bizony eléggé faragatlan talpköve.
Kiss, Róbert Gábor
core +1 more source
No Benefit for Idarucizumab [PDF]
Deutsches Ärzteblatt international, 2016 The review article by Lange et al. on the management of anticoagulation in the setting of endoscopic interventions provides helpful advice and pointers for routine clinical practice (1). Their assessment clashes with the available evidence in one single issue: idarucizumab has thus far not been shown to offer any benefit in terms of the safe ...
openaire +2 more sources
Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolism [PDF]
, 2015 Objective To compare the safety and efficacy of dabigatran to warfarin for the treatment of deep vein thrombosis and pulmonary embolism. Background Venous thromboembolism (VTE) is a disease comprised of two conditions: deep vein thrombosis and pulmonary
Dixon, Dave L., Ogbonna, Kelechi C.
core +3 more sources
Trauma Case Reports, 2018 Introduction: Idarucizumab is the first effective humanized monoclonal antibody fragment developed specifically as a reversal agent for dabigatran, a Direct Oral Anticoagulant. Despite recent trials demonstrating reversal of clinically relevant bleeding,
Gail Edwards +3 more
doaj +1 more source
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management [PDF]
, 2017 Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in the prevention of embolic stroke in non-valvular atrial fibrillation ...
Cheung, KS, Leung, WK
core +1 more source
Two Dabigatran Fast Reversals in a 4-month Period – a Case Report
European Journal of Case Reports in Internal Medicine, 2019 Introduction: Idarucizumab is available for immediate reversal of dabigatran-induced anticoagulation in life-threatening bleeding or urgent surgery in patients with non-valvular atrial fibrillation (nvAF).
Vítor Fagundes, Mari Mesquita
doaj +1 more source
Unraveling the Pharmacokinetic Interaction of Ticagrelor and MEDI2452 (Ticagrelor Antidote) by Mathematical Modeling [PDF]
, 2016 The investigational ticagrelor-neutralizing antibody fragment, MEDI2452, is developed to rapidly and specifically reverse the antiplatelet effects of ticagrelor.
Almquist, Joachim +9 more
core +1 more source